Moderna stock gains 6.98 percent near its 52-week high

Published on 09/25/2026 at 13:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

On September 25, 2026, analysts kept a Hold consensus and set the average 1-year target at USD 76.72. Q2 revenue reached USD 145 million.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) stock was trading at USD 194.82 on Nasdaq on September 24, 2026 at 4:00 p.m. ET, up 6.98 percent from the previous close. The price stood 0.45 percent below the 52-week high of USD 195.71, putting the company at a market capitalization of USD 77.30 billion.

Analysts keep a cautious target

MarketBeat reported on September 25, 2026, that 24 research firms assigned Moderna a consensus rating of Hold. The breakdown was 7 Buy ratings, 13 Hold ratings and 4 Sell ratings, while the average 1-year price objective was USD 76.72.

The gap between the USD 194.82 market price and the USD 76.72 consensus objective makes valuation the central tension in the current setup. Moderna's market capitalization was USD 77.30 billion on September 24, 2026, and trading volume reached 16,480,135 shares.

Revenue edges higher in Q2

Moderna reported USD 145 million of total revenue for the quarter ended June 30, 2026, compared with USD 142 million in Q2 2025, according to MetaTrader. That represents a 2.1 percent year-over-year increase, while net product sales fell from USD 114 million to USD 94 million.

Net loss for Q2 2026 was USD 782 million, or USD 1.97 per share, compared with a USD 825 million loss and USD 2.13 per share in Q2 2025. The loss per share therefore improved by USD 0.16, although the company remained loss-making.

Next results date is November 5

GetSignal lists November 5, 2026 as Moderna's next earnings date. The checkpoint matters because the company entered the reporting cycle with Q2 operating cash flow of negative USD 526 million and cash of USD 1.72 billion as of June 30, 2026.

Moderna stock stays near yearly high

Moderna stock was trading at USD 194.82 on Nasdaq on September 24, 2026 at 4:00 p.m. ET. The 52-week range was USD 22.28 to USD 195.71, and the latest price was 0.45 percent below the upper end of that range.